Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

News & Events

New insight into treatment options for rare childhood brain tumour, 2011 Media Release, Telethon Institute for Child Health Research

A new study led by Australian researchers has outlined for the first time the best treatment options for children suffering from meningioma

News & Events

Continuing the cancer fight

Work by the Institute's Division of Children's Leukaemia and Cancer Research has been recognised with three research grants from the Cancer Council of WA.

News & Events

Apache Energy joins Telethon Institute in cancer research partnership

Apache Energy and the Telethon Institute for Child Health Research today signed a two-year partnership

News & Events

New study examines vacccine to prevent cervical cancer

The Telethon Institute for Child Health Research today announced a new study investigating a vaccine to prevent infection of Human Papilloma Virus (HPV).

News & Events

Global war on brain cancer

Dr Nick Gottardo and Dr Raelene Endersby from The Kids Research Institute Australia are the driving force behind an innovative, global action group on child brain cancer.

Research

Leukaemia

Leukaemia, also spelled leukemia, is a cancer that develops in the bone marrow and results in abnormal white blood cells. It is the most common cancer in children, accounting for almost a third of all childhood & teen cancers.

Research

Editorial: Bench to bedside: translating pre-clinical research into clinical trials for childhood brain tumors

Nick Raelene Gottardo Endersby MBChB FRACP PhD BSc (Hons) PhD Head of Paediatric and Adolescent Oncology and Haematology, Perth Children’s Hospital;

News & Events

Researchers unlock potential new cancer weapon

In an exciting breakthrough for cancer treatment, a new weapon to enable the immune system to combat the disease may have been unlocked.

Research

Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin

Identified romidepsin as a promising therapeutic for mixed lineage leukemia (MLL)-rearranged infant acute lymphoblastic leukemia